PMI's Dividend Yield Expected to Range from 2.1% to 5%

Jan.05.2023
PMI's Dividend Yield Expected to Range from 2.1% to 5%
PMI's 2022 dividend yield is between 2.1% to 5%. It has a market value of 157 billion dollars and owns the IQOS brand.

Phimo International's (PMI) annual dividend yield for 2022 ranges from 2.1% to 5%.


Philip Morris International (PMI) has a market value of $157 billion, which is almost equivalent to the combined total market value of its two competitors. In addition to its leading cigarette brand, Marlboro, the company also owns the top-notch heat-not-burn brand, IQOS.


Since its launch in 2014, IQOS has amassed a customer base of 19.5 million. The growth in sales of IQOS has offset the decline in sales of cigarettes, which is why PMI's overall sales grew by 3.4% in the first nine months of 2022.


Screenshot of Phimo International's revenue-related data. Source: New York Stock Exchange.


Analysts at the New York Stock Exchange predict that the company's earnings will grow at a rate of 2.8% per year over the next five years. The dividend payout ratio for PMI is expected to reach around 92% by 2022.


At first glance, this seems to be in a favorable position. However, due to the minimal capital required for tobacco companies to operate, this allocation rate should be sustainable in the short term. As PMI's dividend growth rate is lower than its earnings in the coming years, dividends are expected to be very safe.


The most significant factor is that investors can purchase the shares of this tobacco giant at a reasonable valuation and receive a 5% dividend yield. The stock's forward P/E ratio of 18.7 is higher than the tobacco industry's average forward P/E ratio of 13.4.


Special Note: This article does not provide any investment references or suggestions.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Global Forum on Nicotine 2026 to explore why prohibition of safer nicotine products risks, and does not protect, public health
Global Forum on Nicotine 2026 to explore why prohibition of safer nicotine products risks, and does not protect, public health
Mar.12
FDA Authorizes Glas Vape but Flavor Hopes Fall Short
FDA Authorizes Glas Vape but Flavor Hopes Fall Short
The FDA has added Glas products to its authorized electronic nicotine delivery systems (ENDS) list, granting Marketing Granted Orders (MGOs) to the Glas G DEVICE and a BLONDE TOBACCO pod. The decision expands the number of FDA-authorized ENDS products to 41, marking the first new authorization since Juul’s approvals in July 2025. However, widely anticipated non-tobacco flavored products were not approved.
Mar.13
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
A patent published on February 24, 2026, by China Tobacco Hubei Industrial Co., Ltd. introduces a “nicotine jelly” product designed to combine rapid and sustained nicotine delivery. By integrating both free and microencapsulated nicotine, the product aims to address key limitations of traditional nicotine replacement therapy (NRT), while also raising new regulatory and product classification questions.
Innovation
Mar.18
Exclusive: Glas says FDA-authorized G2 vape includes age-gating technology
Exclusive: Glas says FDA-authorized G2 vape includes age-gating technology
Glas has confirmed to 2Firsts that its G2 device, which received a FDA Marketing Granted Order (MGO), incorporates age-gating technology. Based on currently public information, this means the FDA has granted an MGO to the first ENDS product confirmed to incorporate age-gating technology, validating 2Firsts’ earlier inference.
Mar.17
2Firsts Holds Second PMTA Compliance Training in Shenzhen, Highlighting U.S. Regulatory Framework and Corporate Compliance Capabilities
2Firsts Holds Second PMTA Compliance Training in Shenzhen, Highlighting U.S. Regulatory Framework and Corporate Compliance Capabilities
2Firsts held its second U.S. PMTA compliance training in Shenzhen, providing a systematic overview of the U.S. regulatory framework for e-cigarettes and corporate compliance strategies. Nearly 20 industry professionals from manufacturing, e-liquid and supply-chain companies attended. Participants who passed the exam received compliance certification. Registration for the third training session will open soon, alongside customized corporate training programs.
Mar.09
More Than 500 Stores in Russia’s Nizhny Novgorod Region Voluntarily Stop Selling Vapes
More Than 500 Stores in Russia’s Nizhny Novgorod Region Voluntarily Stop Selling Vapes
According to the Nizhny Novgorod regional government, 550 stores in the region have voluntarily removed vapes and e-liquids from their product assortments. Regional officials said a public offer encouraging businesses to self-restrict vape sales has been in place since September 2025, and that a large retail chain with more than 40 outlets in Nizhny Novgorod joined the initiative. The regional government also said a federal ban on vape sales is expected in the near future.
Apr.15 by 2FIRSTS.ai